GPRASP2

Across TCGA pan-cancer cohorts, GPRASP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GPRASP2 data layer compared with 18 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher GPRASP2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GPRASP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LUAD, GBM, and UCEC are the cancer types where GPRASP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.929	0.518	.005	17	view →
GBM	DFS	Median	All	0.823	0.611	<.001	12	view →
UCEC	OS	Tertile	II,III,IV	0.554	1.000	.036	8	view →
PDAC	DFS	Median	IV	0.245	0.715	.038	7	view →
LSCC	DFS	Tertile	III,IV	1.000	0.810	.043	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GPRASP2–LUAD (OS)

Open the LUAD breakdown →